Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab

Toshifumi Fujiwara, Takanori Eguchi, Chiharu Sogawa, Kisho Ono, Jun Murakami, Soichiro Ibaragi, Jun-Ichi Asaumi, Stuart K. Calderwood, Kuniaki Okamoto, Ken ichi Kozaki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Overexpression and increased signaling from the epidermal growth factor receptor (EGFR) often changes oral squamous cell carcinoma (OSCC) and thus EGFR is frequently targeted molecularly by the therapeutic antibody cetuximab. We assessed the roles of OSCC-derived extracellular vesicles (EVs), including exosomes in the trafficking of cetuximab and in epithelial-mesenchymal transition (EMT) of epithelial cells. OSCC cells abundantly expressed EGFR, which was secreted from cells with OSCC-EVs upon EGF stimulations. The OSCC-EGFR-EVs were then able to enter into and transform epithelial cells leading to increased mesenchymal traits with increased vimentin and spindle-like shapes. EGF priming of OSCC cells further increased this EMT-initiating effect of the OSCC-EVs. The internalization and pro-EMT effects of the OSCC-EVs were largely blocked by cetuximab. Thus, OSCC-derived EVs transform normal epithelial cells into a mesenchymal phenotype and anti-EGFR therapeutic antibody cetuximab inhibits such a carcinogenic effect of the OSCC-EVs.

Original languageEnglish
Pages (from-to)251-257
Number of pages7
JournalOral Oncology
Volume86
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Exosomes
Epithelial-Mesenchymal Transition
Mouth Neoplasms
Epidermal Growth Factor Receptor
Squamous Cell Carcinoma
Antibodies
Epithelial Cells
Epidermal Growth Factor
Cetuximab
Vimentin
Extracellular Vesicles

Keywords

  • Epidermal growth factor receptor
  • Epithelial-mesenchymal transition
  • Exosome
  • Extracellular vesicle
  • Head and neck cancer
  • Oral cancer

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab. / Fujiwara, Toshifumi; Eguchi, Takanori; Sogawa, Chiharu; Ono, Kisho; Murakami, Jun; Ibaragi, Soichiro; Asaumi, Jun-Ichi; Calderwood, Stuart K.; Okamoto, Kuniaki; Kozaki, Ken ichi.

In: Oral Oncology, Vol. 86, 01.11.2018, p. 251-257.

Research output: Contribution to journalArticle

@article{a125ee82680e42a1ac422a5079ea7e3d,
title = "Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab",
abstract = "Overexpression and increased signaling from the epidermal growth factor receptor (EGFR) often changes oral squamous cell carcinoma (OSCC) and thus EGFR is frequently targeted molecularly by the therapeutic antibody cetuximab. We assessed the roles of OSCC-derived extracellular vesicles (EVs), including exosomes in the trafficking of cetuximab and in epithelial-mesenchymal transition (EMT) of epithelial cells. OSCC cells abundantly expressed EGFR, which was secreted from cells with OSCC-EVs upon EGF stimulations. The OSCC-EGFR-EVs were then able to enter into and transform epithelial cells leading to increased mesenchymal traits with increased vimentin and spindle-like shapes. EGF priming of OSCC cells further increased this EMT-initiating effect of the OSCC-EVs. The internalization and pro-EMT effects of the OSCC-EVs were largely blocked by cetuximab. Thus, OSCC-derived EVs transform normal epithelial cells into a mesenchymal phenotype and anti-EGFR therapeutic antibody cetuximab inhibits such a carcinogenic effect of the OSCC-EVs.",
keywords = "Epidermal growth factor receptor, Epithelial-mesenchymal transition, Exosome, Extracellular vesicle, Head and neck cancer, Oral cancer",
author = "Toshifumi Fujiwara and Takanori Eguchi and Chiharu Sogawa and Kisho Ono and Jun Murakami and Soichiro Ibaragi and Jun-Ichi Asaumi and Calderwood, {Stuart K.} and Kuniaki Okamoto and Kozaki, {Ken ichi}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.oraloncology.2018.09.030",
language = "English",
volume = "86",
pages = "251--257",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab

AU - Fujiwara, Toshifumi

AU - Eguchi, Takanori

AU - Sogawa, Chiharu

AU - Ono, Kisho

AU - Murakami, Jun

AU - Ibaragi, Soichiro

AU - Asaumi, Jun-Ichi

AU - Calderwood, Stuart K.

AU - Okamoto, Kuniaki

AU - Kozaki, Ken ichi

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Overexpression and increased signaling from the epidermal growth factor receptor (EGFR) often changes oral squamous cell carcinoma (OSCC) and thus EGFR is frequently targeted molecularly by the therapeutic antibody cetuximab. We assessed the roles of OSCC-derived extracellular vesicles (EVs), including exosomes in the trafficking of cetuximab and in epithelial-mesenchymal transition (EMT) of epithelial cells. OSCC cells abundantly expressed EGFR, which was secreted from cells with OSCC-EVs upon EGF stimulations. The OSCC-EGFR-EVs were then able to enter into and transform epithelial cells leading to increased mesenchymal traits with increased vimentin and spindle-like shapes. EGF priming of OSCC cells further increased this EMT-initiating effect of the OSCC-EVs. The internalization and pro-EMT effects of the OSCC-EVs were largely blocked by cetuximab. Thus, OSCC-derived EVs transform normal epithelial cells into a mesenchymal phenotype and anti-EGFR therapeutic antibody cetuximab inhibits such a carcinogenic effect of the OSCC-EVs.

AB - Overexpression and increased signaling from the epidermal growth factor receptor (EGFR) often changes oral squamous cell carcinoma (OSCC) and thus EGFR is frequently targeted molecularly by the therapeutic antibody cetuximab. We assessed the roles of OSCC-derived extracellular vesicles (EVs), including exosomes in the trafficking of cetuximab and in epithelial-mesenchymal transition (EMT) of epithelial cells. OSCC cells abundantly expressed EGFR, which was secreted from cells with OSCC-EVs upon EGF stimulations. The OSCC-EGFR-EVs were then able to enter into and transform epithelial cells leading to increased mesenchymal traits with increased vimentin and spindle-like shapes. EGF priming of OSCC cells further increased this EMT-initiating effect of the OSCC-EVs. The internalization and pro-EMT effects of the OSCC-EVs were largely blocked by cetuximab. Thus, OSCC-derived EVs transform normal epithelial cells into a mesenchymal phenotype and anti-EGFR therapeutic antibody cetuximab inhibits such a carcinogenic effect of the OSCC-EVs.

KW - Epidermal growth factor receptor

KW - Epithelial-mesenchymal transition

KW - Exosome

KW - Extracellular vesicle

KW - Head and neck cancer

KW - Oral cancer

UR - http://www.scopus.com/inward/record.url?scp=85054267189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054267189&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2018.09.030

DO - 10.1016/j.oraloncology.2018.09.030

M3 - Article

C2 - 30409309

AN - SCOPUS:85054267189

VL - 86

SP - 251

EP - 257

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -